H.Res. 1285 — 119th Congress
Federal bill
Expressing the sense of the House of Representatives that over 25 years of real-world evidence and hundreds of peer-reviewed studies proving that mifepristone is safe and effective should be respected, and law and policy governing access to lifesaving, time-sensitive medication abortion care in the United States should be equitable, transparent, and based on the best available peer-reviewed evidence-based science.
- Title
- Expressing the sense of the House of Representatives that over 25 years of real-world evidence and hundreds of peer-reviewed studies proving that mifepristone is safe and effective should be respected, and law and policy governing access to lifesaving, time-sensitive medication abortion care in the
- Type
- House simple resolution
- Congress
- 119th Congress
- Chamber of origin
- House
- Introduced
- 2026-05-14
- Latest action
- Referred to the House Committee on Energy and Commerce.
- Latest action date
- 2026-05-14
Organizations that named this bill in federal lobbying filings
- GUTTMACHER INSTITUTE Federal lobbying client (LDA)
Federal lobbying filings naming this bill
U.S. Senate Lobbying Disclosure Act database. A filing names bills, issues and agencies — never the member lobbied — so these rows point only at the client organization, and none of them says any member of Congress was lobbied about this bill. The count is filings in this site's LDA slice, not the
- GUTTMACHER INSTITUTE cited in the filing's issue text 1 filing